Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function - Value of the wearable cardioverter/defibrillator

European Journal of Heart Failure

Volumn 16, Issue 12, 2014, Pages 1331-1336

  Duncker, David ^a   Haghikia, Arash ^a   König, Thorben ^a   Hohmann, Stephan ^a   Gutleben, Klaus Jürgen ^b   Westenfeld, Ralf ^c   Oswald, Hanno ^a   Klein, Helmut ^d   Bauersachs, Johann ^a   Hilfiker Kleiner, Denise ^a   Veltmann, Christian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Heart failure; peripartum; sudden cardiac death; wearable cardioverter defibrillator

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BISOPROLOL; BROMOCRIPTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DEFIBRILLATOR; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; NEW YORK HEART ASSOCIATION CLASS; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; SUDDEN CARDIAC DEATH; TREATMENT DURATION; CARDIOVERSION; COMPLICATION; CONGESTIVE CARDIOMYOPATHY; DEVICES; ECHOGRAPHY; HEART STROKE VOLUME; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PATHOPHYSIOLOGY; PERINATAL PERIOD; PHYSIOLOGY; PREGNANCY COMPLICATION; PROCEDURES; PROSPECTIVE STUDY; VENTRICULAR FIBRILLATION;

ADULT; CARDIOMYOPATHY, DILATED; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION;

EID: 84913601697     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.188     Document Type: Article

References (31)

1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, van Veldhuisen DJ, Watkins H, Shah AJ, Seferovic PM, Elkayam U, Pankuweit S, Papp Z, Mouquet F, McMurray JJV,. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767-778.
2. Chee K-H,. Favourable outcome after peripartum cardiomyopathy: a ten-year study on peripartum cardiomyopathy in a university hospital. Singapore Med J 2013; 54: 28-31.
3. Blauwet LA, Libhaber E, Forster O, Tibazarwa K, Mebazaa A, Hilfiker-Kleiner D, Sliwa K,. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart 2013; 99: 308-313.
4. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Stevenson WG, Zipes DP,. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Heart Rhythm 2008; 5: e1-e21.
5. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C,. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e385-e484.
6. Auricchio A, Klein H, Geller CJ, Reek S, Heilman MS, Szymkiewicz SJ,. Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. Am J Cardiol 1998; 81: 1253-1256.
7. Reek S, Geller JC, Meltendorf U, Wollbrueck A, Szymkiewicz SJ, Klein HU,. Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. Pacing Clin Electrophysiol 2003; 26: 2016-2022.
8. Dillon KA, Szymkiewicz SJ, Kaib TE,. Evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm. J Electrocardiol 2010; 43: 63-67.
9. Epstein AE, Abraham WT, Bianco NR, Kern KB, Mirro M, Rao SV, Rhee EK, Solomon SD, Szymkiewicz SJ,. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol 2013; 62: 2000-2007.
10. Klein HU, Meltendorf U, Reek S, Smid J, Kuss S, Cygankiewicz I, Jons C, Szymkiewicz S, Buhtz F, Wollbrueck A, Zareba W, Moss AJ,. Bridging a temporary high risk of sudden arrhythmic death. experience with the wearable cardioverter defibrillator (WCD). Pacing Clin Electrophysiol 2010; 33: 353-367.
11. Klein HU, Goldenberg I, Moss AJ,. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J 2013; 34: 2230-2242.
12. Rao M, Goldenberg I, Moss AJ, Klein H, Huang DT, Bianco NR, Szymkiewicz SJ, Zareba W, Brenyo A, Buber J, Barsheshet A,. Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. Am J Cardiol 2011; 108: 1632-1638.
13. Prochnau D, Surber R, Kuehnert H, Heinke M, Klein HU, Figulla HR,. Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction. Clin Res Cardiol 2010; 99: 129-131.
14. Peters S, Klein HU,. WCD LifeVest: risk stratification in a case of Tako-Tsubo cardiomyopathy with QT interval prolongation. Herz 2012; 37: 219-221.
15. Collins KK, Silva JNA, Rhee EK, Schaffer MS,. Use of a wearable automated defibrillator in children compared to young adults. Pacing Clin Electrophysiol. 2010; 33: 1119-1124.
16. Everitt MD, Saarel EV,. Use of the wearable external cardiac defibrillator in children. Pacing Clin Electrophysiol 2010; 33: 742-746.
17. Saltzberg MT, Szymkiewicz S, Bianco NR,. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail 2012; 18: 21-27.
18. Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, Czer LSC, Illum S, Hatamizadeh P, Elkayam U,. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009; 15: 645-650.
19. Sliwa K, Forster O, Tibazarwa K, Libhaber E, Becker A, Yip A, Hilfiker-Kleiner D,. Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. Int J Cardiol 2011; 147: 202-208.
20. Whitehead SJ, Berg CJ, Chang J,. Pregnancy-related mortality due to cardiomyopathy: United States, 1991-1997. Obstet Gynecol 2003; 102: 1326-1331.
21. Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, Becker A, Yip A, Klein G, Sliwa K,. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008; 10: 861-868.
22. Fishman GI, Chugh SS, DiMarco JP, Albert CM, Anderson ME, Bonow RO, Buxton AE, Chen P-S, Estes M, Jouven X, Kwong R, Lathrop DA, Mascette AM, Nerbonne JM, O'Rourke B, Page RL, Roden DM, Rosenbaum DS, Sotoodehnia N, Trayanova NA, Zheng Z-J,. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010; 122: 2335-2348.
23. Katritsis DG, Josephson ME,. Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? Europace 2012; 14: 787-794.
24. Disertori M, Quintarelli S, Mazzola S, Favalli V, Narula N, Arbustini E,. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. Europace 2013; 15: 1693-1701.
25. Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, Tchou PJ,. Aggregate national experience with the wearable cardioverter-defibrillator. J Am Coll Cardiol 2010; 56: 194-203.
26. Diao M, Diop IB, Kane A, Camara S, Kane A, Sarr M, Ba SA, Diouf SM,. Electrocardiographic recording of long duration (Holter) of 24 hours during idiopathic cardiomyopathy of the peripartum. Arch Mal Coeur Vaiss 2004; 97: 25-30.
27. Tokuda M, Tedrow UB, Kojodjojo P, Inada K, Koplan BA, Michaud GF, John RM, Epstein LM, Stevenson WG,. Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ Arrhythm Electrophysiol 2012; 5: 992-1000.
28. Yamada T, McElderry HT, Muto M, Okada T, Murakami Y, Doppalapudi H, Epstein AE, Plumb VJ, Kay GN,. Ventricular arrhythmias originating from the epicardial ventricular outflow tract complicated with peripartum cardiomyopathy. J Interv Card Electrophysiol 2008; 25: 53-57.
29. Fett JD, Christie LG, Carraway RD, Murphy JG,. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005; 80: 1602-1606.
30. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA,. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27: 441-446.
31. Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, Roentgen P, Tsikas D, Jordan J, Lichtinghagen R, von CS K, Struman I, Bovy N, Sliwa K, Bauersachs J, Hilfiker-Kleiner D,. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013; 108: 366.